Neumora Therapeutics, Inc. (NMRA) income statement

NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$0.43−0.00 (-0.95%)

Close on Nov 13, 2026Market cap $80.59MP/E –Yield –

Neumora Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Research & Development	176	201	143	92
General & Administrative	60	63	45	31
Operating Expenses	241	263	252	136
Operating Income	-241	-263	-252	-136
Interest Expense	2.01	0	–	–
Interest & Investment Income	8.34	20	–	–
Other Non-Operating Income	4.36	20	16	4.97
Asset Impairment Charges	0.60	0	–	–
Gain (Loss) on Investments	–	–	–	0.02
Gain (Loss) on Sale of Assets	-0.05	0	–	–
Pretax Income	-237	-244	-236	-131
Income Tax Expense	0.13	0.18	0.27	–
Net Income incl. Noncontrolling Interests	-237	-244	-236	-131
Net Income	-237	-244	-236	-131
EPS (Basic)(per share)	-1.45	-1.53	-3.63	-4.81
EPS (Diluted)(per share)	-1.45	-1.53	-3.63	-4.81
Shares Outstanding (Basic, Weighted)(shares)	163	159	65	27
Shares Outstanding (Diluted, Weighted)(shares)	163	159	65	27
EBITDA	-241	-263	-251	-135

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -121.2%

Financial strength

Current ratio: 4.50
Debt to equity: 2.54
Debt to assets: 90.2%
Cash to current liabilities: 420.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.81
Dividend yield: –

See a number that looks wrong?